Zobrazeno 1 - 10
of 14
pro vyhledávání: '"M D Huband"'
Publikováno v:
Антибиотики и Химиотерапия, Vol 60, Iss 11-12, Pp 51-51 (2020)
Externí odkaz:
https://doaj.org/article/9f986feb091b4891a645826f6595def6
Publikováno v:
Antimicrobial agents and chemotherapy. 66(11)
We evaluated the in vitro activity of manogepix and comparator agents against 1,435 contemporary fungal isolates collected worldwide from 73 medical centers in North America, Europe, the Asia-Pacific region, and Latin America during 2020. Of the isol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e796164aef234066d7aca92ed0809d5
https://pubmed.ncbi.nlm.nih.gov/36286491
https://pubmed.ncbi.nlm.nih.gov/36286491
Publikováno v:
Antimicrobial Agents and Chemotherapy. 39:2123-2127
Certain new fluoroquinolones have high activity against enterococci. Against Enterococcus faecalis (n = 18), MICs at which 90% of the isolates were inhibited were as follows (in micrograms per milliliter): clinafloxacin, 0.125; CI-990, 0.5; and PD 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e00ebbeac14b082f5fd5a8c3c58afbc
https://doi.org/10.1128/aac.39.9.2123
https://doi.org/10.1128/aac.39.9.2123
Autor:
Josephine A. Sesnie, Rocco D. Gogliotti, M D Huband, Martin A. Shapiro, Joseph P. Sanchez, Michael A. Cohen, Stephen J. Gracheck, John M. Domagala
Publikováno v:
ChemInform. 27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::297f8aac2919b21e4114964d2156533b
https://doi.org/10.1002/chin.199610198
https://doi.org/10.1002/chin.199610198
Autor:
Carl L. Heifetz, Steven L. Yoder, Gregory E. Roland, Gail B. Mailloux, Michael A. Cohen, M D Huband
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 14:403-415
Sparfloxacin (CI-978, AT-4140 and PD 131501) is a new antimicrobial agent of the piperazinyl quinolone class. Relative to other quinolones, it is a potent antistaphylococcal and antistreptococcal drug in vitro: The microbroth 90% minimum inhibitory c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e22a4761f22d70d3abd89f9a6ced9df6
https://doi.org/10.1016/0732-8893(91)90067-p
https://doi.org/10.1016/0732-8893(91)90067-p
Autor:
Steven L. Yoder, Gail B. Mailloux, M D Huband, Carl L. Heifetz, Michael A. Cohen, Gregory E. Roland
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 14:245-258
Three new aminopyrrolidine-substituted fluorocyclopropyl quinolones--PD 117596, PD 124816, and PD 127391--were tested for in vitro antibacterial activity against 349 bacterial strains, which are primarily clinical isolates. The minimum inhibitory con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c97d1b240b9b900fbb2437c2bc73e6
https://doi.org/10.1016/0732-8893(91)90039-i
https://doi.org/10.1016/0732-8893(91)90039-i
Autor:
Steven L. Yoder, Gail B. Mailloux, M D Huband, Gregory E. Roland, Carl L. Heifetz, Michael A. Cohen, John M. Domagala
Publikováno v:
Antimicrobial Agents and Chemotherapy. 35:141-146
PD 131628 is a new aminopyrrolidine-substituted fluorocyclopropyl naphthyridine quinolone which possesses high in vitro activity against a wide spectrum of bacterial species. The MICs for greater than or equal to 90% of strains were 0.125 to 0.25 mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b8786aba248c106ab35880a92741724
https://doi.org/10.1128/aac.35.1.141
https://doi.org/10.1128/aac.35.1.141
Publikováno v:
Drugs. 58:151-153
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd72670588644670117ee4a7317ad424
https://doi.org/10.2165/00003495-199958002-00040
https://doi.org/10.2165/00003495-199958002-00040
Autor:
John M. Domagala, M D Huband, Dean Vo, Yuntao Song, Rajeshwar Singh, Sara A. Wold, Huang Liren, Maxwell Cummings, Diane Alessi, Stephen J. Gracheck, Eric R. Olson, Gregg Johnson, Ruth A. Van Bogelen, Martin A. Shapiro
Publikováno v:
Resolving the Antibiotic Paradox ISBN: 9781461372202
Bacterial resistance to the currently available antibiotics is a worldwide problem with catastrophic potential (Kunin, 1993; Berkowitz, 1995; Domagala and Sanchez, 1997). In the US, overall mortality from infectious diseases has increased 58% with de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc38a2ee189e4ed971aa9b5b6b20cb96
https://doi.org/10.1007/978-1-4615-4897-3_14
https://doi.org/10.1007/978-1-4615-4897-3_14
Autor:
Gregory E. Roland, Jeffrey W. Gage, Steven L. Yoder, M D Huband, Stephen J. Gracheck, Michael A. Cohen
Publikováno v:
The Journal of antimicrobial chemotherapy. 40(2)
Clinafloxacin and trovafloxacin are two new fluoroquinolones for which few comparative data are available. When MICs of ciprofloxacin against Gram-positive and Gram-negative nosocomial species were compared, clinafloxacin was the most potent although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f649369cc36515a123194dd4d27883b0
https://pubmed.ncbi.nlm.nih.gov/9301985
https://pubmed.ncbi.nlm.nih.gov/9301985